Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Mammary Carcinoma, Human”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableStudy completedNCT05584644
What this trial is testing

Describe the Breast Cancer Patient Population, Treatment, and Results in Indian Patients Receiving Combinations of the Medicines Called Palbociclib for Advanced Breast Cancer

Who this might be right for
Breast CancerBreast CarcinomaBreast Neoplasms+2 more
Pfizer 150
Not applicableStudy completedNCT02580799
What this trial is testing

Study of Human Epidermal Growth Receptor (HER2) Status Evaluation in Breast Cancer Pathology Samples

Who this might be right for
Breast Cancer
Hoffmann-La Roche 30
Testing effectiveness (Phase 2)Active Not RecruitingNCT05323955
What this trial is testing

Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib

Who this might be right for
Brain MetastasesHuman Epidermal Growth Factor 2 Positive Carcinoma of BreastAdvanced Breast Cancer
Carey Anders, M.D. 48
Early research (Phase 1)Study completedNCT04834778
What this trial is testing

HC-5404-FU to Establish the Maximum Tolerated Dose (MTD)

Who this might be right for
Renal Cell CarcinomaGastric CancerMetastatic Breast Cancer+2 more
HiberCell, Inc. 23
Testing effectiveness (Phase 2)Study completedNCT02091960
What this trial is testing

Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast Cancer

Who this might be right for
HER2 AmplifiedAdvanced Breast CancerHuman Epidermal Growth Factor Receptor 2 (HER2)
Astellas Pharma Global Development, Inc. 103
Testing effectiveness (Phase 2)Ended earlyNCT04227327
What this trial is testing

Study Evaluating Abemaciclib + Aromatase Inhibitors in HR+, HER2- Advanced Breast Cancer Patients (HERMIONE-7)

Who this might be right for
Advanced Breast Cancer
University of Milano Bicocca 31
Early research (Phase 1)Ended earlyNCT02078752
What this trial is testing

PF-06647263 In Patients With Advanced Solid Tumors

Who this might be right for
NeoplasmsTriple-Negative Breast Cancer
Pfizer 60
Not applicableStudy completedNCT01934478
What this trial is testing

Radiotherapy Alternates Human Epidermal Growth Factor 2 (Her2) Expression in Human Breast Cancer

Who this might be right for
Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
Qingdao Central Hospital 5
Testing effectiveness (Phase 2)Active Not RecruitingNCT04398914
What this trial is testing

Pyrotinib, Trastuzumab, Pertuzumab and Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer

Who this might be right for
Breast Cancer Invasive
Shanghai Jiao Tong University School of Medicine 216
Testing effectiveness (Phase 2)Study completedNCT03219476
What this trial is testing

Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer

Who this might be right for
Breast CancerInvasive Breast Cancer
Medical College of Wisconsin 37
Early research (Phase 1)Study completedNCT01937689
What this trial is testing

Study of Pyrotinib in Patients With Human Epidermalgrowth Factor Receptor 2 (HER2) Positive Advanced Breast Cancer

Who this might be right for
Breast Cancer
Jiangsu HengRui Medicine Co., Ltd. 40
Testing effectiveness (Phase 2)Ended earlyNCT03709082
What this trial is testing

Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer

Who this might be right for
HER2-positive Breast CancerBreast Cancer Metastatic
University of Kansas Medical Center 3
Early research (Phase 1)Study completedNCT04991480
What this trial is testing

ART4215 for the Treatment of Advanced or Metastatic Solid Tumors

Who this might be right for
Advanced CancerMetastatic CancerBreast Cancer
Artios Pharma Ltd 93
Testing effectiveness (Phase 2)Study completedNCT04505826
What this trial is testing

A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer

Who this might be right for
Hormone Receptor Positive Breast CarcinomaHER2-negative Breast Cancer
Olema Pharmaceuticals, Inc. 153
Early research (Phase 1)Looking for participantsNCT07623369
What this trial is testing

A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors

Who this might be right for
Solid TumorNon-small Cell Lung CancerHepatocellular Carcinoma+9 more
Huahui Health 299
Testing effectiveness (Phase 2)Study completedNCT00120692
What this trial is testing

Treatment for Patients Suffering From Anemia Due to Chemotherapy

Who this might be right for
Breast CancerAnemia
Amgen
Not applicableEnded earlyNCT01506700
What this trial is testing

Real Time Optical Coherence Tomography (OCT) of Human Tissue

Who this might be right for
Breast Cancer
Diagnostic Photonics, Inc. 5
Early research (Phase 1)Study completedNCT03246009
What this trial is testing

Fusion Protein rHSA/GCSFclinical Study on Breast Cancer Patients

Who this might be right for
Chemotherapy-induced NeutropeniaCancer, Breast
Tianjin SinoBiotech Ltd. 24
Testing effectiveness (Phase 2)Ended earlyNCT03584009
What this trial is testing

A Phase II Study Comparing The Efficacy Of Venetoclax + Fulvestrant Vs. Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy

Who this might be right for
Estrogen Receptor-positive (ER+)/Human Epidermal Growth Factor Receptor (HER2)-Negative Locally Advanced or Metastatic Breast Cancer
Hoffmann-La Roche 103
Large-scale testing (Phase 3)Looking for participantsNCT07413939
What this trial is testing

RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive

Who this might be right for
HER2-positive Breast Cancer
Hoffmann-La Roche 650
Next Page